Genenta Science S.p.A. (GNTA)
Company Description
Genenta Science is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors.
We have developed a novel biologic platform which involves the ex-vivo gene transfer of a therapeutic candidate into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs).
Our technology is designed to turn TEMs, which normally have an affinity for and travel to tumors, into a “Trojan Horse” to counteract cancer progression and to prevent tumor relapse.
Our technology is not target dependent, and therefore we believe it can be used as a treatment for a broad variety of cancers. Our lead product candidate, Temferon, was developed using our platform and carries an interferon-alpha (IFN-α) payload.
Because Temferon delivers the IFN-α payload directly to the tumor, we believe it will demonstrate clinical activity without the side effect profile of systemic delivery of IFN-α.
We are currently conducting a Phase 1/2a dose-escalation clinical trial with Temferon in newly diagnosed uMGMT-GBM patients in Italy. We anticipate completing patient enrollment and treatment by the second quarter of 2022.
| Country | Italy |
| Founded | 2014 |
| IPO Date | Dec 15, 2021 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 4 |
| CEO | Pierluigi Paracchi |
Contact Details
Address: Via Olgettina No. 58 Milan 20132 Italy | |
| Phone | 39 02 26 43 46 81 |
| Website | genenta.com |
Stock Details
| Ticker Symbol | GNTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $11.50 |
| CIK Code | 1838716 |
Key Executives
| Name | Position |
|---|---|
| Pierluigi Paracchi | Vice Chairman, Chief Executive Officer and GM |
| Dr. Luigi Naldini M.D., Ph.D. | Co-Founder and Chairman of the Executive Scientific Board |
| Dr. Bernard Rudolph Gentner M.D. | Founder and Member of the Executive Scientific Board |
| Richard B. Slansky | Chief Financial Officer |
| Dr. Stefania Mazzoleni Ph.D. | Scientific Project Manager and Communications Officer |
| Dr. Carlo Russo M.D. | Chief Medical Officer and Head of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 11, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Apr 29, 2022 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] |
| Feb 25, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 18, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Dec 16, 2021 | SEC STAFF LETTER | SEC Staff Letter: REDACTED EXHIBIT |
| Dec 15, 2021 | 424B1 | Prospectus [Rule 424(b)(1)] |
| Dec 15, 2021 | 424B1 | Prospectus [Rule 424(b)(1)] |
| Dec 15, 2021 | EFFECT | Notice of Effectiveness |
| Dec 14, 2021 | F-1MEF | Registration statement to add securities to prior Form F-1 registration [Rule 462(b)] |
| View All SEC Filings | ||